Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
Local Institution - 0041, Boston, Massachusetts Local Institution - 0037, Durham, North Carolina Australia
Local Institution - 0007, Camperdown, New South Wales Local Institution - 0008, Brisbane, Queensland Local Institution - 0013, Clayton, Victoria Brazil
Local Institution - 0040, Salvador, Estado de Bahia Local Institution - 0039, Porto Alegre Local Institution - 0038, São Paulo Czechia
Local Institution - 0004, Prague, Praha 5 Revmatologicky ustav, Prague France
CHU Strasbourg-Hautepierre, Strasbourg, Alsace Hopital Claude Huriez - CHU de Lille, Lille, Nord Germany
Local Institution - 0023, Düsseldorf, North Rhine-Westphalia Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin, Berlin Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden Local Institution - 0031, Hamburg Israel
Sheba Medical Center, Ramat Gan, Central District Hadassah Medical Center, Jerusalem Poland
Uniwersyteckie Centrum Kliniczne, Gdansk, Pomeranian Voivodeship Szpital Specjalistyczny nr 1 w Bytomiu, Bytom, Silesian Voivodeship Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy w Gliwicach, Gliwice, Silesian Voivodeship Local Institution - 0017, Lodz, Łódź Voivodeship Romania
ARENSIA Exploratory Medicine, Cluj-Napoca, Cluj Fundeni Clinical Institute, Bucharest Spain
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona] Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya [Cataluña] Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad de